Platelet glycoprotein IIb/IIIa inhibition and atheroembolism during bypass graft angioplasty: A cup half full

Circulation

Volumn 106, Issue 24, 2002, Pages 2994-2996

  Kereiakes, Dean J ^a  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

Angioplasty; Editorials; Embolism; Glycoproteins

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST;

ANGIOPLASTY; ARTERY EMBOLISM; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CONTRAST ECHOCARDIOGRAPHY; EDITORIAL; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HUMAN; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVASCULARIZATION; SAPHENOUS VEIN GRAFT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; EMBOLISM, CHOLESTEROL; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTRAOPERATIVE COMPLICATIONS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RESEARCH DESIGN; RISK; SAPHENOUS VEIN; TREATMENT OUTCOME;

EID: 0037058878     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000041222.31560.65     Document Type: Editorial

References (22)

1. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/lIIa integrin in ischemic heart disease. Circulation. 1998;98:2829-2835.
2. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2001;37:2059-2065.
3. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 2002;113:1-6.
4. Kereiakes DJ, Lincoff AM, Anderson K, et al. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. Am J Cardiol. 20021;90:628-630.
5. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/lIIa receptor in high risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
6. Mak KH, Challapalli R, Eisenberg MJ, et al. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. Am J Cardiol. 1997;80:985-988.
7. Hong MK, Mehran R, Dangas G, et al. Are we making progress with percutaneous saphenous vein graft treatment? A comparison of 1990 to 1994 and 1995 to 1998 results. J Am Coll Cardiol. 2001;38:150-154.
8. Ellis SG, Lincoff AM, Miller D, et al. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. J Am Coll Cardiol. 1998;32:1619-1623.
9. Mathew V, Grill DE, Scott CG, et al. The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. J Am Coll Cardiol. 1999;34:1163-1169.
10. Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/lIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: A pooled analysis of five randomized clinical trials. Circulation. 2002;106:3063-3067.
11. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition and prevention. Circulation. 1998;97: 916-931.
12. Webb JG, Carere RG, Virmani R, et al. Retrieval, and analysis of particulate debris after saphenous vein graft intervention. J Am Coll Cardiol. 1999;34:468-475.
13. Grube E, Schofer JJ, Webb J, et al. Evaluation of a balloon occlusion and aspiration system for protection from distal embolization during stenting in saphenous vein grafts. Am J Cardiol. 2002;89:941-945.
14. Schofer J, Chevalier B, Seth A, et al. Stenting of saphenous vein grafts: Initial experience with a distal filter protection system in a Multicenter trial. Circulation. 2001;104(suppl II):11-622. Abstract.
15. Hori M, Inoue M, Kitakaze M, et al. Role of adenosine in hyperemic response of coronary blood flow in microembolization. Am J Physiol. 1986;250:H509-H518.
16. Baim DS, Wahr D, George B, et al. Randomized trial of distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105:1285-1290.
17. Tanaka A, Kawarabayashi T, Nishibori Y, et al. No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation. 2002;105:2148-2152.
18. Erbel R, Heusch G. Coronary microembolization: Its role in acute coronary syndromes and interventions. Herz. 1999;7:558-575.
19. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765-772.
20. Michaels AD, Appleby M, Otten MH, et al. Pretreatment with intragraft verapamil prior to PCI of saphenous vein graft lesions: Results of the VAPOR trial. J Invas Cardiol. 2002;14:299-302.
21. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation. 2001;104:163-167.
22. Seshiah PN, Kereiakes DJ, Vasudevan SV, et al. Activated monocytes induce smooth muscle cell death: Role of macrophage colony-stimulating factor and cell contact. Circulation. 2002;105:174-180.